Humacyte Analyst Price Targets - Benzinga

Humacyte Inc

HUMANASDAQ

Trade with Public

Trade with Public

$0.4281

0.037.54%

Últ. Act.: Nov 3, 1:08 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Humacyte Analyst Price Targets - Benzinga

Humacyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Humacyte (HUMA).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$5Upside to Avg. PT+1093.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$1
Aug 13, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$2→$1
Jul 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 17, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$2→$1
Jun 16, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 11, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$4
Jun 8, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 1, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$1→$2
May 26, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$3
May 14, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$1→$2
May 13, 2026	BTIG	Ryan Zimmerman	PT Cut	Buy	$3→$2
Apr 28, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$3
Apr 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 8, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$4→$2
Mar 31, 2026	Benchmark	Bruce D. Jackson	Downgrade	Buy→Speculative Buy	$10→$1
Mar 30, 2026	Piper Sandler	Allison Bratzel	PT Cut	Neutral	$3→$1
Mar 30, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$4→$1
Mar 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25

Analyst Ratings News

PRO
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5

Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $3 to $4.

Benzinga Newsdesk